Charles Schwab Investment Management Inc. Has $4.55 Million Position in OPKO Health, Inc. $OPK

Key Points

• Charles Schwab Investment Management Inc. has reduced its stake in OPKO Health, Inc. by 21.6%, owning 2,741,986 shares after selling 755,420 shares in the first quarter.
• OPKO Health reported a loss per share of ($0.19) for the last quarter, missing estimates, and a revenue of $156.80 million, which was below expectations of $165.74 million.
• CEO Phillip Frost acquired 675,000 shares of OPKO Health for approximately $891,000, bringing his total ownership to 214,676,448 shares.

Charles Schwab Investment Management Inc. lowered its holdings in OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 21.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,741,986 shares of the biotechnology company's stock after selling 755,420 shares during the period. Charles Schwab Investment Management Inc. owned about 0.35% of OPKO Health worth $4,552,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Oak Thistle LLC bought a new position in OPKO Health in the first quarter valued at $26,000. Cerity Partners LLC bought a new position in OPKO Health in the first quarter valued at $36,000. Wealth Enhancement Advisory Services LLC lifted its stake in OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 12,417 shares during the last quarter. Pallas Capital Advisors LLC acquired a new stake in OPKO Health in the first quarter valued at $43,000. Finally, Mercer Global Advisors Inc. ADV lifted its stake in OPKO Health by 105.6% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 43,167 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 22,167 shares during the last quarter. Institutional investors own 64.63% of the company's stock.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 675,000 shares of the company's stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $1.32 per share, for a total transaction of $891,000.00. Following the purchase, the chief executive officer directly owned 214,676,448 shares of the company's stock, valued at $283,372,911.36. This trade represents a 0.32% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 49.69% of the stock is owned by company insiders.

OPKO Health Stock Performance

Shares of NASDAQ OPK traded down $0.04 during mid-day trading on Monday, reaching $1.38. 1,663,914 shares of the company were exchanged, compared to its average volume of 2,347,663. The company's 50-day simple moving average is $1.34 and its 200-day simple moving average is $1.45. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $1.10 billion, a P/E ratio of -5.52 and a beta of 1.40. OPKO Health, Inc. has a twelve month low of $1.11 and a twelve month high of $2.04.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). The company had revenue of $156.80 million for the quarter, compared to analyst estimates of $165.74 million. OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%.The business's quarterly revenue was down 13.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.01) EPS. As a group, research analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Analysts Set New Price Targets

OPK has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a research note on Tuesday, July 8th. Finally, Zacks Research upgraded shares of OPKO Health from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $2.75.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.